close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorGezondheidszorg

7.19 -8.87

Strong Buy

Prijsupdate 14 jan 2026, 20:54 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.07

Max

7.82

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+70.73% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

48M

150M

Vorige openingsprijs

16.06

Vorige sluitingsprijs

7.19

Nieuwssentiment

By Acuity

30%

70%

81 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jan 2026, 19:05 UTC

Belangrijke Marktbewegers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

DJ

Lezen

13 jan 2026, 23:41 UTC

Marktinformatie

Nikkei May Rise on Japan Election Hopes -- Market Talk

DJ

Lezen

13 jan 2026, 23:41 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

13 jan 2026, 23:33 UTC

Marktinformatie

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

DJ

Lezen

13 jan 2026, 23:13 UTC

Acquisities, Fusies, Overnames

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

DJ

Lezen

13 jan 2026, 23:10 UTC

Acquisities, Fusies, Overnames

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

DJ

Lezen

13 jan 2026, 23:03 UTC

Marktinformatie

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

DJ

Lezen

13 jan 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

DJ

Lezen

13 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

DJ

Lezen

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

DJ

Lezen

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

DJ

Lezen

13 jan 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

DJ

Lezen

13 jan 2026, 21:15 UTC

Acquisities, Fusies, Overnames

VERSANT Completes Acquisition Of Free TV Networks >VSNT

DJ

Lezen

13 jan 2026, 21:08 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

DJ

Lezen

13 jan 2026, 20:39 UTC

Marktinformatie

Silver Settles at Another New High -- Market Talk

DJ

Lezen

13 jan 2026, 20:21 UTC

Marktinformatie

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

DJ

Lezen

13 jan 2026, 20:17 UTC

Marktinformatie

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

DJ

Lezen

13 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

DJ

Lezen

13 jan 2026, 19:03 UTC

Winsten

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

DJ

Lezen

13 jan 2026, 18:50 UTC

Winsten

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

DJ

Lezen

13 jan 2026, 17:54 UTC

Marktinformatie

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

DJ

Lezen

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

DJ

Lezen

13 jan 2026, 17:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

DJ

Lezen

13 jan 2026, 17:49 UTC

Marktinformatie

Analysts Call For Potential Record Ethanol Output -- Market Talk

DJ

Lezen

13 jan 2026, 17:38 UTC

Marktinformatie

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

DJ

Lezen

13 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

13 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

13 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

DJ

Lezen

13 jan 2026, 17:19 UTC

Marktinformatie

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

DJ

Lezen

13 jan 2026, 17:15 UTC

Marktinformatie

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

70.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14 USD  70.73%

Hoogste 19 USD

Laagste 10 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

81 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

MDT

Medtronic PLC

98.5

↑ +2.11%

A

Agilent Technologies Inc

146.08

↓-0.25%

VEEV

Veeva Systems Inc

218.2

↓-4.44%

HQY

HealthEquity Inc

85.69

↑ +1.95%

PHR.US

Phreesia Inc

16.1

↓-2.6%
help-icon Live chat